PURPOSE: To prospectively study the pharmacokinetics and toxicity profile of docetaxel in elderly patients with cancer. PATIENTS AND METHODS: Docetaxel was administered at a dose 75 mg/m(2) once every 3 weeks to 25 elderly cancer patients aged >/= 65 years and 26 cancer patients aged younger than 65 years. Pharmacokinetic studies and toxicity assessments were performed during the first cycle of therapy. RESULTS: Of 51 patients treated, 20 aged >/= 65 years (median, 71 years; range, 65 to 80 years) and 20 aged younger than 65 years (median, 53 years; range, 26 to 64 years) were assessable for pharmacokinetic studies, and 39 were assessable for toxicity. Patient characteristics were similar (P >/= .15) between the two cohorts. Mean docetaxel clearance was not altered in the elderly versus younger patients: 30.1 L/h (standard deviation [SD] 18.3 L/h) v 30.0 L/h (SD, 14.8 L/h; P = .98). The percentage of patients with grade 4 and febrile neutropenia was higher in the elderly (63% and 16%, respectively) versus younger (30% and 0%, respectively) cohort, although this observation did not reach a level of statistical significance (P = .056). From logistic regression analysis, the odds ratio for a patient aged 65 years was 1.98 for developing grade 4 neutropenia compared with a patient aged 50 years (P = .091). CONCLUSION: Docetaxel plasma pharmacokinetics are unaltered in elderly patients. Patients aged >/= 65 years appear to be more sensitive to docetaxel-induced neutropenia.
PURPOSE: To prospectively study the pharmacokinetics and toxicity profile of docetaxel in elderly patients with cancer. PATIENTS AND METHODS: Docetaxel was administered at a dose 75 mg/m(2) once every 3 weeks to 25 elderly cancerpatients aged >/= 65 years and 26 cancerpatients aged younger than 65 years. Pharmacokinetic studies and toxicity assessments were performed during the first cycle of therapy. RESULTS: Of 51 patients treated, 20 aged >/= 65 years (median, 71 years; range, 65 to 80 years) and 20 aged younger than 65 years (median, 53 years; range, 26 to 64 years) were assessable for pharmacokinetic studies, and 39 were assessable for toxicity. Patient characteristics were similar (P >/= .15) between the two cohorts. Mean docetaxel clearance was not altered in the elderly versus younger patients: 30.1 L/h (standard deviation [SD] 18.3 L/h) v 30.0 L/h (SD, 14.8 L/h; P = .98). The percentage of patients with grade 4 and febrile neutropenia was higher in the elderly (63% and 16%, respectively) versus younger (30% and 0%, respectively) cohort, although this observation did not reach a level of statistical significance (P = .056). From logistic regression analysis, the odds ratio for a patient aged 65 years was 1.98 for developing grade 4 neutropenia compared with a patient aged 50 years (P = .091). CONCLUSION:Docetaxel plasma pharmacokinetics are unaltered in elderly patients. Patients aged >/= 65 years appear to be more sensitive to docetaxel-induced neutropenia.
Authors: Marie-Rose B S Crombag; Aurelia H M de Vries Schultink; Jacobine G C van Doremalen; Hans-Martin Otten; Andries M Bergman; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema Journal: Drugs Aging Date: 2019-04 Impact factor: 3.923
Authors: Arti Hurria; Constance T Cirrincione; Hyman B Muss; Alice B Kornblith; William Barry; Andrew S Artz; Linda Schmieder; Rafat Ansari; William P Tew; Douglas Weckstein; Jeffrey Kirshner; Kayo Togawa; Kurt Hansen; Vani Katheria; Richard Stone; Ilene Galinsky; John Postiglione; Harvey Jay Cohen Journal: J Clin Oncol Date: 2011-02-28 Impact factor: 44.544
Authors: Marie-Rose B S Crombag; Thomas P C Dorlo; Ellen van der Pan; Anoek van Straten; Andries M Bergman; Nielka P van Erp; Jos H Beijnen; Alwin D R Huitema Journal: Pharm Res Date: 2019-11-15 Impact factor: 4.200
Authors: S D Baker; J Verweij; G A Cusatis; R H van Schaik; S Marsh; S J Orwick; R M Franke; S Hu; E G Schuetz; V Lamba; W A Messersmith; A C Wolff; M A Carducci; A Sparreboom Journal: Clin Pharmacol Ther Date: 2008-05-28 Impact factor: 6.875